1396007-65-0

Basic information

• Product Name: 1-{4'-[1-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-1H-[1,2,3]triazol-4-yl]biphenyl-4-yl}cyclopropanecarboxylic acid
• Synonyms: 1-{4'-[1-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-1H-[1,2,3]triazol-4-yl]biphenyl-4-yl}cyclopropanecarboxylic acid
• CAS NO: 1396007-65-0
• Molecular Weight: 482.539
• Mol File: 1396007-65-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-{4'-[1-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-1H-[1,2,3]triazol-4-yl]biphenyl-4-yl}cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-{4'-[1-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-1H-[1,2,3]triazol-4-yl]biphenyl-4-yl}cyclopropanecarboxylic acid(1396007-65-0)
• EPA Substance Registry System: 1-{4'-[1-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-1H-[1,2,3]triazol-4-yl]biphenyl-4-yl}cyclopropanecarboxylic acid(1396007-65-0)

Safety Data

• Hazardous Substances Data: 1396007-65-0(Hazardous Substances Data)

Upstream product

• 1396008-17-5 1-{4'-[1-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-1H-[1,2,3]-triazol-4-yl]biphenyl-4-yl}cyclopropanecarboxylic acid methyl ester 
• 1396008-13-1 [5-(4-bromo-phenyl)-3-methyl-3H-[1,2,3]triazol-4-yl]carbamic acid (R)-1-phenyl-ethyl ester 
• 1396007-85-4 1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid methyl ester 
• 1396008-10-8 5-(4-bromo-phenyl)-3-methyl-3H-[1,2,3]triazole-4-carboxylic acid 
• 1396008-08-4 5-(4-bromo-phenyl)-3-methyl-3H-[1,2,3]triazole-4-carboxylic acid ethyl ester 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 1159489-46-9 [4-(1'-carboxycyclopropyl)phenyl]boronic acid 
• 1402465-85-3 (R)-1-phenylethyl 4-(4-chlorophenyl)-1-methyl-1H-1,2,3-triazol-5-ylcarbamate 
• 1402465-84-2 4-(4-chlorophenyl)-1-methyl-1H-1,2,3-triazole-5-carboxylic acid 
• 1402465-83-1 4-(4-chlorophenyl)-1-methyl-1H-1,2,3-triazole-5-carbaldehyde 

Relevant articles and documents

N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful

COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS

The present invention relates to compounds of Formula (1), or pharmaceutically acceptable salts thereof and their pharmaceutical compositions, wherein variables are as defined herein, which are useful as modulators of the activity of lysophosphatidic acid (LPA).